1. The morbidity of treatment for patients with stage I endometrial cancer: Results from a randomized trial
- Author
-
Creutzberg, CL, van Putten, WLJ, Koper, PC, Lybeert, MLM, Jobsen, JJ, Warlam-Rodenhuis, CC, De Winter, KAJ, Lutgens, LCHW, van den Bergh, ACM, van der Steen-Banasik, E, Beerman, H, van Lent, M, and Guided Treatment in Optimal Selected Cancer Patients (GUTS)
- Subjects
COMPLICATIONS ,CARCINOMA ,BRACHYTHERAPY ,acute and late complications ,IRRADIATION ,POSTOPERATIVE RADIOTHERAPY ,EXTERNAL-BEAM ,RADIATION-THERAPY ,endometrial cancer ,PATHOLOGICAL STAGE ,adverse effects ,randomized trial ,HYSTERECTOMY ,ADJUVANT RADIOTHERAPY ,radiotherapy ,treatment-related morbidity - Abstract
Purpose: To compare the treatment complications for patients with Stage I endometrial cancer treated with surgery and pelvic radiotherapy (RT) or surgery alone in a multicenter randomized trial. Methods and Materials: The Postoperative Radiation Therapy in Endometrial Carcinoma (PORTEC) trial included patients with endometrial cancer confined to the uterine corpus, either Grade 1 or 2 with more than 50% myometrial invasion, or Grade 2 or 3 with less than 50% myometrial invasion. Surgery consisted of an abdominal hysterectomy and oophorectomy, without lymphadenectomy. After surgery, patients were randomized to receive pelvic RT (46 Gy), or no further treatment. A total of 715 patients were randomized. Treatment complications were graded using the French-Italian glossary. Results: The analysis was done at a median follow-up duration of 60 months. 691 patients were evaluable. Five-year actuarial rates of late complications (Grades 1-4) were 26% in the RT group and 4% in the control group (p
- Published
- 2001